# Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement

> **NCT04323566** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Uppsala University Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Obsessive-Compulsive Disorder
- Obsessive-Compulsive Behavior
- Schizophrenia
- Delusional Disorder
- Brief Psychotic Disorder
- Schizo Affective Disorder
- Other Psychoses
- Unspecified Psychosis

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04323566
- **Lead sponsor:** Uppsala University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-05-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04323566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04323566, "Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04323566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*